Dewi Tungadi, Nurhayana Sennang, Benny Rusli



Multidrug-resistant Acinetobacter baumannii (MDRAB) is a strain of Acinetobacter baumannii which is resistant to three or more classes of antibiotics. As prevalence of MDRAB increases, the antibiotics of choice become limited. Identification of MDRAB is required to manage and control infection.


This was a retrospective study, conducted in Dr. Wahidin Sudirohusodo General Hospital of Makassar, dated from January to December 2016. Bacterial identification and antimicrobial susceptibility testing (AST) were performed using VITEK 2. The patient data were obtained from electronic medical records.

Results and Discussion

A total of 323 Acinetobacter baumannii isolates were obtained, consisted of 188 isolates in January-June 2016 and 36 of which was MDRAB (19.15%) with the average length-of-stay 33 days; and 135 isolates in July-December 2016 and 31 of which was MDRAB (22.96%) with the average length-of-stay 27 days. MDRAB was mostly discovered from patients using 3 or more medical devices and on single antibiotic therapy. MDRAB isolates were mostly obtained in sputum and pus specimens, and majority of patients had respiratory diseases. The result of AST showed 100% and 96% susceptibility to Polymyxin B; 71.43% and 54.84% susceptibility to Amikacin; 66.67% and 50% susceptibility to Trimethoprim/Sulfamethoxazole in January-June and July-December 2016, respectively.

Conclusion and Suggestions

The prevalence of MDRAB in our hospital in 2016 was high, suggesting the needs to improve hospital infection prevention and control. Polymyxin B, Amikacin, and Trimethoprim/Sulfamethoxazole are the antibiotics of choice to treat MDRAB.


Acinetobacter baumannii, MDRAB, antibiotic resistance

Full Text:



Central for Disease Control and Prevention. Acinetobacter in Healthcare Settings [Online]. 2010 November 24 [cited 2017 July 29]. Available from :

World Health Organization. Multidrug-Resistant Acinetobacter baumannii (MDRAB) [Online]. 2010 November 1 [cited 2017 August 2]. Available from :

Cunha BA. Acinetobacter [Online]. 2016 March 15 [cited 2017 August 2]. Available from :

Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathogens and Disease. 2014 (0):1-10.

Zarilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. International Journal of Antimicrobial Agents 41 (2013): 11-19.

Tuon FF, Rocha JL, Merlini AB. Combined therapy for multi-drug-resistant Acinetobacter baumannii infection – is there evidence outside the laboratory?. Journal of Medical Microbiology (2015), 64, 951-959.

Bigot S and Salcedo SP. The influence of two-partner secretion systems on the virulence of Acinetobacter baumannii. Virulence. 2017; 0(0): 1-2.

Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options. Clinical Infectious Diseases 2008;46: 1254-63.

Hasan B, Perveen K, Olsen B and Zahra R. Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan. Journal of Medical Microbiology (2014), 63 : 50-55.

Rahman V, Anggraini D, Fauziah D. Pola Resistensi Acinetobacter baumannii yang Diisolasi di Intensive Care Unit (ICU) RSUD Arifin Achmad Provinsi Riau Periode 1 Januari hingga 31 Desember 2014. Jurnal Online Mahasiswa FK (2015), 2:2.

Anggraini D, Yovi I, Rahayu PY. Gambaran Infeksi oleh Acinetobacter baumannii Resisten Meropenem di RSUD Arifin Achmad Provinsi Riau Periode 1 Januari – 31 Desember 2014 [Online]. 2014 [cited 2017 August 23]. Available from : GAMBARAN-INFEKSI-OLEH-ACINETOBACTER-BAUMANNII-RESISTEN-MEROPENEM-DI-RSUD-ARIFIN-ACHMAD-PROVINSI-RIAU-PERIODE-01-JANUARI-2014-31-DESEMBER-2014

Torres HA, Vazquez EG, Yague G, Gomez JG. Multidrug resistant Acinetobacter baumannii: Clinical Update and New Highlights. Rev Esp Quimioter 2010;23(1):12-19.

Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization. Emerging Infectious Diseases 2007;13(1): 97-103.

Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Antimicrobial Agents and Chemotherapy 2016; 60(7): 3921-33.

Urban C, Mariano N, Rahal JJ. Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI21 and Cecropin P1. Antimicrobial Agents and Chemotherapy 2001; 45(3): 994-5.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.